<DOC>
	<DOCNO>NCT01569984</DOCNO>
	<brief_summary>This single-centre , single-arm open-label proof-of-concept study analyze image ( DCE-CT , CEUS Quantitative US ) effect neoadjuvant bevacizumab SBRT colorectal metastasis liver . Patients receive 2 dos bevacizumab 5mg/kg IV prior SBRT . The second dose bevacizumab give 2 week first dose bevacizumab within 48 hour start first dose SBRT . The SBRT prescription dose 60 Gy 6 fraction , deliver alternate weekday 2 week . Total SBRT dose determine size target lesion , liver spar organs-at-risk dose constraint . DCE-CT , CEUS Quantitative US perform within 7 day prior first dose bevacizumab , second dose bevacizumab within 7 day complete SBRT .</brief_summary>
	<brief_title>Radiosensitization AVASTIN® ( Bevacizumab ) With Stereotactic Body Radiotherapy Colorectal Liver Metastasis</brief_title>
	<detailed_description>This single-centre , single-arm open-label proof-of-concept study analyze image ( DCE-CT , CEUS Quantitative US ) effect neoadjuvant bevacizumab SBRT colorectal metastasis liver . Patients receive 2 dos bevacizumab 5mg/kg IV prior SBRT . The second dose bevacizumab give 2 week first dose bevacizumab within 48 hour start first dose SBRT . The SBRT prescription dose 60 Gy 6 fraction , deliver alternate weekday 2 week . Total SBRT dose determine size target lesion , liver spar organs-at-risk dose constraint . DCE-CT , CEUS Quantitative US perform within 7 day prior first dose bevacizumab , second dose bevacizumab within 7 day complete SBRT .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Histological and/or cytological diagnosis colorectal cancer liver metastases confirm image scan 2 . 13 liver metastatic lesion confirm image scan 3 . Maximum size target metastatic lesion 6 cm less 4 . At least 700 cc liver uninvolved tumour 5 . Previous liver resection , systemic therapy local ablation therapy allow . Extrahepatic disease allow maximum involved organ ( include liver ) 3 less ( i.e . oligometastases ) . 6 . ChildPugh 's A liver function 7 . Male female : Age ≥ 18 year 8 . Life expectancy &gt; 3 month 9 . ECOG PS &lt; 2 10 . Prior bevacizumab permit long last dose &gt; 28 day registration 11 . Laboratory Requirements within 7 day prior registration : Hematology neutrophils ≥ 1.5 x 109/L platelet ≥ 100 x 109/L hemoglobin ≥ 90 g/L Biochemistry bilirubin ≤ 1.5 x upper limit normal serum creatinine ≤ 1.5 x upper limit normal AST ≤ 3 x upper limit normal ( ≤ 5 x liver metastasis present ) ALT ≤ 3 x upper limit normal ( ≤ 5 x liver metastasis present ) INR ≤ 1.3 Urinalysis Proteinuria ≤ grade 1 ( dipstick ) 12 . Patients willing provide informed consent . 13 . Patients must accessible treatment follow . Patients register trial must treat follow participate centre 1 . Major surgical procedure , open biopsy significant traumatic injury within 28 day prior registration ( i.e . patient must recover less equal grade 1 major surgery ) , anticipation need major surgical procedure within 7 week chemoradiotherapy . 2 . Known clinical radiological evidence CNS metastasis . 3 . Patients past current history ( within last 2 year ) malignancy , except indication study curatively treat basal squamous skin cancer insitu cancer cervix . Prior treatment localized prostate cancer permit treatment great 5 year ago patient currently biochemical evidence recurrence . 4 . Active hepatitis ( infectious noninfectious ) 5 . Patients known history present encephalopathy 6 . Gross clinically detectable ascites 7 . Women childbearing potential positive pregnancy test baseline lactating . Postmenopausal woman must amenorrheic least 12 month consider non childbearing potential . Females patient must pregnant become pregnant study 6 month last dose bevacizumab . 8 . Sexually active male female ( childbearing potential ) unwilling practice contraception study . Patients childbearing potential must willing use reliable method birth control . i.e . : double barrier method , oral contraceptive , implant , dermal contraception , longterm injectable contraceptive , intrauterine device tubal ligation study . 9 . Prior radiotherapy right upper quadrant liver 10 . Known hypersensitivity reaction bevacizumab 11 . Known hypersensitivity Chinese hamster ovary cell product recombinant human humanise antibody 12 . Uncontrolled hypertension , define SBP &gt; 150/100 one occasion respond therapy antihypertensive agent treat 2 antihypertensive medication . 13 . Any serious intercurrent illness cardiovascular disease , HIV neurological disease . 14 . Patients take approved investigational drug/anticancer treatment ( ongoing androgen ablation oral prednisone permit ) study period , include chemotherapy , biological response modifier , immunotherapy , surgery radiotherapy . 15 . Patients concurrently participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Colorectal</keyword>
</DOC>